增强CT联合血清ESM1、UCHL1对非小细胞肺癌靶向治疗的疗效评估分析  

Application of Enhanced CT Combined with Serum ESM-1 and UCHL1 in the Evaluation of the Efficacy of Targeted Therapy for Non-small Cell Lung Cancer

作　　者：刘远红 吴雪健 刘华 雷蕾[2] LIU Yuan-hong;WU Xue-jian;LIU Hua;LEI Lei(Department of Radiology,363 Hospital,Chengdu 610041,Sichuan Province,China;Department of Medical Oncology,Chengdu Sixth People's Hospital,Chengdu 610000,Sichuan Province,China)

机构地区：[1]三六三医院放射科,四川成都610041 [2]成都市第六人民医院肿瘤科,四川成都610000

出　　处：《中国CT和MRI杂志》2024年第7期50-52,共3页Chinese Journal of CT and MRI

基　　金：成都市卫生健康委员会(2021110)。

摘　　要：目的探究增强CT联合血清内皮细胞特异性分子-1(ESM-1)、泛素羧基末端水解酶L1(UCHL1)评估非小细胞肺癌(NSCLC)靶向治疗疗效。方法选取我院2020年3月-2022年10月收治的112例NSCLC患者为研究对象(NSCLC组),均进行盐酸厄洛替尼片治疗,另选取同期在我院行健康体检者112例为对照组。酶联免疫吸附法(ELISA)测定血清ESM1、UCHL1水平;比较NSCLC患者治疗前后及不同治疗效果NSCLC患者血清ESM-1、UCHL1水平及增强CT参数;评估增强CT联合血清ESM-1、UCHL1对NSCLC靶向治疗疗效。结果靶向治疗后总有效61例,总有效率54.46%,无效51例,无效率45.54%;NSCLC组患者血清ESM-1、UCHL1水平均显著高于对照组(P<0.05);NSCLC患者治疗后,血清ESM-1、UCHL1水平及灌注值均显著降低(P<0.05),PH、M/A、Tp差异无统计学意义(P>0.05);治疗前后,总有效组NSCLC患者血清ESM-1、UCHL1水平均显著低于无效组(P<0.05),治疗前总有效组与无效组灌注值与PH差异无统计学意义(P>0.05),治疗后总有效组灌注值与PH均降低(P<0.05),无效组灌注值与PH均升高(P<0.05);一致性结果显示,灌注值与PH判定结果与实体瘤疗效评价具有较高的一致性(Kappa=0.677、0.624,P均<0.001);灌注值联合血清ESM-1、UCHL1及PH联合血清ESM-1、UCHL1评估靶向治疗疗效的敏感度分别为91.80%、86.89%,特异度为92.16%、86.27%,准确度为91.96%、86.61%,均显著高于增强CT、血清ESM-1、UCHL1单独检测(P<0.05)。结论通过增强CT联合血清ESM-1、UCHL1有助于评估靶向治疗的疗效,可指导临床制定和调整进一步诊治方案。Objective To evaluate the effect of enhanced CT combined with serum endothelial cell specific molecule-1(ESM-1)and ubiquitin carboxyl terminal hydrolase L1(UCHL1)in evaluating the targeted therapy of non-small cell lung cancer(NSCLC).Methods A total of 112 patients with NSCLC admitted to our hospital from March 2020 to October 2022 were selected as the study subjects(NSCLC group),all of whom were treated with erlotinib hydrochloride tablets,and 112 patients who underwent physical examination in our hospital during the same period were collected as the control group.Enzyme linked immunosorbent assay(ELISA)was applied to measure serum levels of ESM-1 and UCHL1;the serum ESM-1,UCHL1 levels,and enhanced CT parameters were compared before and after treatment,and among patients with different treatment effects;the efficacy of enhanced CT combined with serum ESM-1 and UCHL1 in targeted therapy of NSCLC was evaluated.Results After targeted therapy,61 cases were effective,the total effective rate was 54.46%,51 cases were ineffective,and the ineffective rate was 45.54%;the serum levels of ESM-1 and UCHL1 in the NSCLC group were obviously higher than those in the control group(P<0.05);after treatment,the levels of serum ESM-1 and UCHL1,and perfusion values in NSCLC patients were obviously reduced(P<0.05),while there was no statistically obvious difference in pH,M/A,and Tp(P>0.05);before and after treatment,the serum levels of ESM-1 and UCHL1 in the total effective group were obviously lower than those in the ineffective group(P<0.05),before treatment,there was no statistically obvious difference in perfusion value and pH between the total effective group and the ineffective group(P>0.05),and after treatment,the perfusion value and pH of the total effective group decreased(P<0.05),while the perfusion value and pH of the ineffective group increased(P<0.05);the consistency results showed that there was a high consistency between the perfusion value and PH determination results and the evaluation of solid tumor efficacy(Kappa=0

关 键 词：非小细胞肺癌 增强CT ESM-1 UCHL1 

分 类 号：R734.2[医药卫生—肿瘤]